drugset / Trial / NCT05752461

SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

NCT05752461

Phase 2 Completed 353 enrolled Beijing Suncadia Pharmaceuticals Co., Ltd
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty

Timeline

Start
2023-04-12
Primary completion
2024-04-12
Completion
2024-06-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enoxaparin sodium Other / unclassified 40 mg Subcutaneous
Subject SHR-2004 Monoclonal antibody Subcutaneous

Indications

No indication recorded.